Prognostic Value of Dynamic Susceptibility Contrast-Enhanced and Diffusion-Weighted MR Imaging in Patients with Glioblastomas

REFERENCES

1. 1.↵
   2. Ohgaki H,
   3. Kleihues P

   . Epidemiology and etiology of gliomas. Acta Neuropathol 2005;109:93–108

   CrossRefPubMedWeb of Science
2. 2.↵
   2. Behin A,
   3. Hoang-Xuan K,
   4. Carpentier AF, et al

   . Primary brain tumours in adults. Lancet 2003;361:323–31

   CrossRefPubMedWeb of Science
3. 3.↵
   2. Stark AM,
   3. Nabavi A,
   4. Mehdorn HM, et al

   . Glioblastoma multiforme: report of 267 cases treated at a single institution. Surg Neurol 2005;63:162–69

   CrossRefPubMedWeb of Science
4. 4.↵
   2. Kleihues P,
   3. Ohgaki H

   . Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro Oncol 1999;1:44–51

   Abstract/FREE Full Text
5. 5.↵
   2. Lacroix M,
   3. Abi-Said D,
   4. Fourney DR, et al

   . A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection of resection and survival. J Neurosurg 2001;95:190–98

   CrossRefPubMedWeb of Science
6. 6.↵
   2. Mangiola A,
   3. Maira G,
   4. De Bonis P, et al

   . Glioblastoma multiforme in the elderly: a therapeutic challenge. J Neurooncol 2006;76:159–63

   CrossRefPubMed
7. 7.↵
   2. Galanis E,
   3. Buckner J,
   4. Kimmel D, et al

   . Gene amplification as a prognostic factor in primary and secondary high-grade malignant gliomas. Int J Oncol 1998;13:717–24

   PubMedWeb of Science
8. 8.↵
   2. Shinojima N,
   3. Tada K,
   4. Shiraishi S, et al

   . Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 2003;63:6962–70

   Abstract/FREE Full Text
9. 9.↵
   2. Law M,
   3. Young RJ,
   4. Babb JS, et al

   . Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247:490–98

   CrossRefPubMedWeb of Science
10. 10.↵
    2. Spampinato MV,
    3. Schiarelli C,
    4. Cianfoni A, et al

    . Correlation between cerebral blood volume measurements by perfusion-weighted magnetic resonance imaging and two-year progression-free survival in gliomas. Neuroradiol J 2013;26:385–95

    Abstract/FREE Full Text
11. 11.↵
    2. Bisdas S,
    3. Kirkpatrick M,
    4. Giglio P, et al

    . Cerebral blood volume measurements by perfusion-weighted MR imaging in gliomas: ready for prime time in predicting short-term outcome and recurrent disease? AJNR Am J Neuroradiol 2009;30:681–88

    Abstract/FREE Full Text
12. 12.↵
    2. Bampoe J,
    3. Bernstein M

    . The role of surgery in low grade gliomas. J Neurooncol 1999;42:259–69

    CrossRefPubMed
13. 13.↵
    2. Murakami R,
    3. Hirai T,
    4. Sugahara T, et al

    . Grading astrocytic tumors by using apparent diffusion coefficient parameters: superiority of a one versus two-parameter pilot method. Radiology 2009;251:838–45

    CrossRefPubMedWeb of Science
14. 14.↵
    2. Bode MK,
    3. Ruohonen J,
    4. Nieminen MT, et al

    . Potential of diffusion imaging in brain tumors: a review. Acta Radiol 2006;47:585–94

    FREE Full Text
15. 15.↵
    2. Murakami R,
    3. Sugahara T,
    4. Nakamura H, et al

    . Malignant supratentorial astrocytoma treated with postoperative radiation therapy: prognostic value of pretreatment quantitative diffusion-weighted MR imaging. Radiology 2007;243:493–99

    CrossRefPubMedWeb of Science
16. 16.↵
    2. Higano S,
    3. Yun X,
    4. Kumabe T, et al

    . Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. Radiology 2006;241:839–46

    CrossRefPubMedWeb of Science
17. 17.↵
    2. Nakamura H,
    3. Murakami R,
    4. Hirai T, et al

    . Can MRI-derived factors predict the survival in glioblastoma patients treated with postoperative chemoradiation therapy? Acta Radiol 2013;54:214–20

    Abstract/FREE Full Text
18. 18.↵
    2. Oh J,
    3. Henry RG,
    4. Pirzkall A, et al

    . Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume. J Magn Reson Imaging 2004;19:546–54

    CrossRefPubMed
19. 19.↵
    2. Stupp R,
    3. Mason WP,
    4. van den Bent MJ, et al

    . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–96

    CrossRefPubMedWeb of Science
20. 20.↵
    2. Paul I,
    3. Bhattacharya S,
    4. Chatterjee A, et al

    . Current understanding on EGFR and Wnt/β-catenin signaling in glioma and their possible crosstalk. Genes Cancer 2013;4:427–46

    CrossRefPubMed
21. 21.↵
    2. Yiin JJ,
    3. Hu B,
    4. Schornack PA, et al

    . ZD6474, a multitargeted inhibitor for receptor tyrosine kinases, suppresses growth of gliomas expressing an epidermal growth factor receptor mutant, EGFRvIII, in the brain. Mol Cancer Ther 2010;9:929–41

    Abstract/FREE Full Text
22. 22.↵
    2. Johnson G,
    3. Wetzel SG,
    4. Cha S, et al

    . Measuring blood volume and vascular transfer constant from dynamic, T(2)*-weighted contrast-enhanced MRI. Magn Reson Med 2004;51:961–68

    CrossRefPubMed
23. 23.↵
    2. Knopp EA,
    3. Cha S,
    4. Johnson G, et al

    . Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging. Radiology 1999;211:791–98

    CrossRefPubMedWeb of Science
24. 24.↵
    2. Rosen BR,
    3. Belliveau JW,
    4. Buchbinder BR, et al

    . Contrast agents and cerebral hemodynamics. Magn Reson Med 1991;19:285–92

    CrossRefPubMedWeb of Science
25. 25.↵
    2. Rosen BR,
    3. Belliveau JW,
    4. Vevea JM, et al

    . Perfusion imaging with NMR contrast agents. Magn Reson Med 1990;14:249–65

    CrossRefPubMedWeb of Science
26. 26.↵
    2. Spampinato MV,
    3. Wooten C,
    4. Dorlon M, et al

    . Comparison of first-pass and second-bolus dynamic susceptibility perfusion MRI in brain tumors. Neuroradiology 2006;48:867–74

    CrossRefPubMed
27. 27.↵
    2. Wetzel SG,
    3. Cha S,
    4. Johnson G, et al

    . Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproducibility study. Radiology 2002;224:797–803

    CrossRefPubMedWeb of Science
28. 28.↵
    2. Wang S,
    3. Kim S,
    4. Chawla S, et al

    . Differentiation between glioblastomas, solitary brain metastases, and primary cerebral lymphomas using diffusion tensor and dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol 2011;32:507–14

    Abstract/FREE Full Text
29. 29.↵
    2. Lev MH,
    3. Ozsunar Y,
    4. Henson JW, et al

    . Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas. AJNR Am J Neuroradiol 2004;25:214–21

    Abstract/FREE Full Text
30. 30.↵
    2. Law M,
    3. Oh S,
    4. Babb JS, et al

    . Low-grade gliomas: dynamic susceptibility weighted contrast-enhanced perfusion MR imaging-prediction of patient clinical response. Radiology 2006;238:658–67

    CrossRefPubMedWeb of Science
31. 31.↵
    2. Law M,
    3. Yang S,
    4. Babb JS, et al

    . Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol 2004;25:746–55

    Abstract/FREE Full Text
32. 32.↵
    2. Mangla R,
    3. Ginat DT,
    4. Kamalian S, et al

    . Correlation between progression free survival and dynamic susceptibility contrast MRI perfusion in WHO grade III glioma subtypes. J Neurooncol 2014;116:325–31

    CrossRefPubMed
33. 33.↵
    2. Hirai T,
    3. Murakami R,
    4. Nakamura H, et al

    . Prognostic value of perfusion MR imaging of high-grade astrocytomas: long-term follow-up study. AJNR Am J Neuroradiol 2008;29:1505–10

    Abstract/FREE Full Text
34. 34.↵
    2. Cha S,
    3. Tihan T,
    4. Crawford F, et al

    . Differentiation of low grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol 2005;26:266–73

    Abstract/FREE Full Text
35. 35.↵
    2. Essock-Burns E,
    3. Philips JJ,
    4. Molinaro AM, et al

    . Comparison of DSC-MRI post-processing techniques in predicting microvascular histopathology in patients newly diagnosed with GBM. J Magn Reson Imaging 2013;38:388–400

    CrossRefPubMed
36. 36.↵
    2. Morita N,
    3. Wang S,
    4. Chawla S, et al

    . Dynamic susceptibility contrast perfusion weighted imaging in grading of non-enhancing astrocytomas. J Magn Reson Imaging 2010;32:803–08

    CrossRefPubMed
37. 37.↵
    2. Wu WC,
    3. Chen CY,
    4. Chung HW, et al

    . Discrepant MR spectroscopic and perfusion imaging results in a case of malignant transformation of cerebral glioma. AJNR Am J Neuroradiol 2002;23:1775–78

    Abstract/FREE Full Text
38. 38.↵
    2. Nelson SJ

    . Assessment of therapeutic response and treatment planning for brain tumors using metabolic and physiological MRI. NMR Biomed 2011;24:734–49

    PubMedWeb of Science
39. 39.↵
    2. Yamasaki F,
    3. Sugiyama K,
    4. Ohtaki M, et al

    . Glioblastoma treated with postoperative radiochemotherapy: prognostic value of apparent diffusion coefficient at MR imaging. Eur J Radiol 2010;73:532–37

    CrossRefPubMed
40. 40.↵
    2. Pierallini A,
    3. Bonamini M,
    4. Pantano P, et al

    . Radiological assessment of necrosis in glioblastoma: variability and prognostic value. Neuroradiology 1998;40:150–53

    CrossRefPubMedWeb of Science
41. 41.↵
    2. Ru P,
    3. Williams TM,
    4. Chakravarti A, et al

    . Tumor metabolism of malignant gliomas. Cancers 2013;5:1469–84

    CrossRefPubMed
42. 42.↵
    2. Miyagami M,
    3. Katayama Y

    . Angiogenesis of glioma: evaluation of ultrastructural characteristics of microvessels and tubular bodies (Weibel-Palade) in endothelial cells and immunohistochemical findings with VEGF and p53 protein. Med Mol Morphol 2005;38:36–42

    CrossRefPubMed
43. 43.↵
    2. Kapoor GS,
    3. Gocke TA,
    4. Chawla S, et al

    . Magnetic resonance perfusion weighted imaging defines angiogenic subtypes of oligodendroglioma according to1p19q and EGFR status. J Neurooncol 2009;92:373–86

    CrossRefPubMed
44. 44.↵
    2. Abdulrauf SI,
    3. Edvardsen K,
    4. Ho KL, et al

    . Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma. J Neurosurg 1998;88:513–20

    CrossRefPubMedWeb of Science
45. 45.↵
    2. Shaw EG,
    3. Tatter SB,
    4. Lesser GJ, et al

    . Current controversies in the radiotherapeutic management of adult low-grade glioma. Semin Oncol 2004;31:653–58

    CrossRefPubMed
46. 46.↵
    2. Stupp R,
    3. Baumert BG

    . Promises and controversies in the management of low-grade glioma. Ann Oncol 2003;14:1695–96

    FREE Full Text
47. 47.↵
    2. Xie K,
    3. Yang J,
    4. Zhang ZG, et al

    . Semi-automated brain tumor and edema segmentation using MRI. Eur J Radiol 2005;56:12–19

    CrossRefPubMed
48. 48.↵
    2. Kaus MR,
    3. Warfield SK,
    4. Nabavi A, et al

    . Automated segmentation of MR images of brain tumors. Radiology 2001;218:586–91

    CrossRefPubMedWeb of Science